IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Values First Advisors Inc.

Values First Advisors Inc. lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 17.7% during the fourth quarter, Holdings Channel reports. The firm owned 2,615 shares of the company’s stock after buying an additional 394 shares during the period. Values First Advisors Inc.’s holdings in IDEXX Laboratories were worth $1,452,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in IDXX. Moneta Group Investment Advisors LLC raised its position in shares of IDEXX Laboratories by 121,647.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock worth $3,038,192,000 after purchasing an additional 7,441,162 shares during the period. Norges Bank acquired a new stake in IDEXX Laboratories in the 4th quarter valued at approximately $336,416,000. Morgan Stanley increased its position in IDEXX Laboratories by 36.0% in the 4th quarter. Morgan Stanley now owns 986,232 shares of the company’s stock valued at $402,344,000 after acquiring an additional 260,926 shares during the period. Alliancebernstein L.P. increased its position in IDEXX Laboratories by 6.4% in the 2nd quarter. Alliancebernstein L.P. now owns 3,592,832 shares of the company’s stock valued at $1,804,428,000 after acquiring an additional 214,529 shares during the period. Finally, Winslow Capital Management LLC increased its position in IDEXX Laboratories by 24.9% in the 3rd quarter. Winslow Capital Management LLC now owns 689,873 shares of the company’s stock valued at $301,661,000 after acquiring an additional 137,621 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

NASDAQ IDXX traded up $0.36 on Friday, reaching $539.93. 290,111 shares of the stock traded hands, compared to its average volume of 397,320. The firm’s fifty day simple moving average is $548.25 and its 200 day simple moving average is $501.97. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.42. The company has a market cap of $44.86 billion, a price-to-earnings ratio of 53.62, a P/E/G ratio of 2.96 and a beta of 1.27. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.20. The business had revenue of $901.60 million during the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The company’s revenue was up 8.8% compared to the same quarter last year. During the same period last year, the company posted $2.05 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 11.15 EPS for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In other news, SVP George Fennell sold 8,198 shares of the firm’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the sale, the senior vice president now owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CFO Brian P. Mckeon sold 23,326 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the completion of the sale, the chief financial officer now directly owns 29,718 shares in the company, valued at $16,939,557.18. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP George Fennell sold 8,198 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the sale, the senior vice president now owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The disclosure for this sale can be found here. Insiders sold a total of 43,524 shares of company stock valued at $24,871,960 over the last quarter. Company insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on IDXX shares. BNP Paribas started coverage on IDEXX Laboratories in a research report on Thursday, December 7th. They issued an “outperform” rating and a $602.00 target price on the stock. JPMorgan Chase & Co. raised their target price on IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price on the stock. in a research report on Tuesday, January 30th. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Wednesday, December 20th. Finally, William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Friday, January 5th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $591.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.